Clinical Trials · NCT01029886

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Name: Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Liraglutide Exenatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 912
Start date: Jan 2010
Locations: 108 sites, 21 countries
Primary endpoint: Change in HbA1c From Baseline to Week 26

View Liraglutide compound reference